Pfizer’s $6.49 Billion Prevnar Franchise Faces a New Challenger

Vaxcyte's VAX-31 vaccine met primary endpoints in a Phase 3 trial, matching Pfizer's Prevnar 20 and Merck's Capvaxive on most serotypes. Prevnar generated $6.49B in 2025, about 10% of Pfizer's revenue, while Capvaxive brought in $759M. VAX-31's approval is not expected until 2028, with Pfizer having more at stake due to its larger franchise.

Original reporting
Published Oct 6, 2026, 10:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 11:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pfizer’s $6.49 Billion Prevnar Franchise Faces a New Challenger — source image
Decision brief

The 30-second read

$PFEBearishMed
01

Why it matters

The trial results introduce a new competitive threat that could affect future sales forecasts for both incumbents while providing a growth catalyst for Vaxcyte.

02

Market read

New Phase 3 data could shift investor sentiment on the three companies, especially impacting Pfizer and Merck's vaccine revenue outlook.

03

What to watch

Insurance reimbursement policies and existing contracts could mitigate immediate impact.

Relevance 8/10Novelty 9/10Timing: today

Background

Pfizer and Merck rely on multi-valent pneumococcal vaccines for a significant portion of their revenue. Vaxcyte, a biotech, is developing a 31-valent vaccine.

Company-level read

Ticker impact

$PFEBearishHigh confidence
Context

Vaxcyte's VAX-31 trial showed comparable efficacy to Pfizer's Prevnar 20, posing a competitive threat to Pfizer's $6.49B vaccine franchise.

Expected impact

likely downside as market prices in competitive risk

Evidence & confidence

Trial data is fresh and directly challenges a major revenue source.

$MRKBearishHigh confidence
Context

VAX-31 also outperformed Merck's Capvaxive on most shared serotypes, increasing competitive risk for Merck's pneumococcal vaccine.

Expected impact

potential pressure on stock as investors reassess growth outlook

Evidence & confidence

New trial results highlight Merck's smaller market exposure and competitive disadvantage.

$PCVXBullishHigh confidence
Context

Vaxcyte announced its Phase 3 trial met all primary endpoints, positioning VAX-31 for FDA filing in H1 2028.

Expected impact

likely upside as investors price in future market entry

Evidence & confidence

First report of successful pivotal trial provides material new information.

Market effects

May reshape competitive dynamics in the pneumococcal vaccine market.

US adult vaccine market could see pricing pressure.

Potential ripple effects for global vaccine manufacturers.

Counterpoint

If VAX-31 faces regulatory delays, Pfizer and Merck may retain market share longer.

Key entities

  • Pfizer Inc.

    Manufacturer of Prevnar 20, a leading pneumococcal vaccine.

  • Merck & Co.

    Producer of Capvaxive, a newer pneumococcal vaccine.

  • Vaxcyte Inc.

    Biotech developing the 31-valent VAX-31 vaccine.

Related articles

$MRKHigh

Why Merck (MRK) Stock Is Down Today

Merck (MRK) shares fell 3.8% after the company discontinued the BELLWAVE clinical program for nemtabrutinib, citing potential risks outweighing benefits in a Phase 3 trial. The decision impacts multiple studies, marking a pipeline setback for the drugmaker. Merck's latest earnings report had shown revenue growth and pipeline activity before this development.